Citigroup
ODTX

Citigroup’s Odyssey Therapeutics ODTX Stock Holding History

Citigroup’s Portfolio ODTX Stock Details ODTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.56K Buy
+511
New +$8.96K ﹤0.01% 5246

Other funds holding ODTX

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
LMC
Lightspeed Management Company Menlo Park, California $2.4B AUM 7.07% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FCMV
Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Citigroup's ODTX Position: Q2 2026 in Review

Citigroup opened a new position in Odyssey Therapeutics (ODTX) in Q2 2026: 511 shares worth $9.56K. The stake represents ﹤0.01% of the portfolio and ranks #5246 among its holdings.

50 funds tracked by Wall St. Rank hold ODTX as of Q2 2026.

  • Citigroup held 511 shares of Odyssey Therapeutics worth $9.56K as of Q2 2026.
  • Odyssey Therapeutics was a new Citigroup position in Q2 2026.
  • Odyssey Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #5246 holding.
  • 50 funds tracked by Wall St. Rank held Odyssey Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.